Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 51Capecitabine 42Irinotecan 29Bevacizumab 21Radiotherapy 17Cetuximab 12Folfox protocol 11Chemoradiotherapy 11Neoadjuvant Therapy 10Chemotherapy, Adjuvant 9Surgical Procedures, Operative 6Drug Therapy 6XELOX 5Panitumumab 4Laparoscopy 4FOLFOXIRI protocol 4Transanal Endoscopic Microsurgery 3Radiation 3Octreotide 3IFL protocol 3Floxuridine 3Diathermy 3Celecoxib 3vatalanib 2spartalizumab 2Trinitrotoluene 2Tegafur 2Semaxinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Rectal Neoplasms × vatalanib × Clear all
NCT00056459 2020-02-10

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Novartis

Phase 3 Completed
1,168 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00056446 2017-03-06

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Novartis

Phase 3 Completed
855 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡